A phase 2 trial of R1507, a monoclonal antibody to the insulin‐like growth factor‐1 receptor (IGF‐1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and…

Overview of attention for article published in Cancer (0008543X), May 2014

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 1 Google+ post.

R1507 is safe and well tolerated but has limited activity in patients with recurrent or refractory bone... R1507 is safe and…

This page shows the most recent Google+ posts that mention this research output.

Click here to find out how to access more activity.